Treatment of Buffy Coat Platelets in Platelet Additive Solution with the Mirasol^® Pathogen Reduction Technology System

By  

Transfusion Medicine and Hemotherapy, Vol. 40, Iss. 1, 2013-01 ,pp. : 44-48

Karger

Access to resources Recommend Favorite

Practical Experience of Implementing the INTERCEPT™ Blood System for Buffy Coat Platelets in a Blood Center

By  

Transfusion Medicine and Hemotherapy, Vol. 31, Iss. 1, 2004-02 ,pp. : 32-36

Karger

Access to resources Recommend Favorite

Buffy coat volume reduction for optimization of leucapheresis harvests produced by the autoMNC program

By  

VOX SANGUINIS, Vol. 108, Iss. 1, 2015-01 ,pp. : 89-95

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metabolomic analysis of platelets during storage: a comparison between apheresis‐ and buffy coat–derived platelet concentrates

By  

TRANSFUSION, Vol. 55, Iss. 2, 2015-02 ,pp. : 301-313

John Wiley & Sons Inc

Access to resources Recommend Favorite

In vitro affinity reduction of biologic response modifiers from production buffy coat platelets exposed to recombinant protein receptors

By  

TRANSFUSION, Vol. 55, Iss. 8, 2015-08 ,pp. : 1919-1926

John Wiley & Sons Inc

Access to resources Recommend Favorite